Sinopharm account plan
Pharmaceutical distribution and research
At a glance
Sinopharm Group runs China's largest national drug and medical device distribution network, with FY2025 revenue of RMB575,167.88 million.
Sinopharm Group Co. Ltd. (HKEX 01099) is the core listed subsidiary of the state-owned China National Pharmaceutical Group (CNPGC) and runs the largest national pharmaceutical and medical device distribution network in China. It distributes drugs, medical devices and consumables to hospitals, distributors, retail pharmacies and primary health institutions, runs the Guoda Drugstore and specialty pharmacy chains, and produces pharmaceutical products, chemical reagents and laboratory supplies. FY2025 revenue was RMB575,167.88 million (-1.60%) and profit attributable to owners of the parent RMB7,155.09 million (+1.50%). Headcount was 90,447 at mid-2026, down from 94,910 at end-2025. CNPGC owns 51% of Sinopharm Industrial Investment, which holds 50.36% of the Company, and holds 6.64% directly.
Business units
Pharmaceutical distribution
72.79% of FY2025 revenue (RMB435,391.60 million)Distribution of drugs to hospitals, other distributors, pharmacies and clinics, plus logistics and value-added services for manufacturers. Revenue fell 2.02% in FY2025 on volume-based procurement and price cuts, but in H1 2026 national negotiated varieties sales grew 27% and innovative drugs 30%. CSO marketing services are growing at double digits.
Medical device distribution
19.32% of FY2025 revenue (RMB115,537.72 million)Distribution of medical devices and consumables plus installation and maintenance. Consumables grow while IVD products and equipment decline under centralised procurement; the Group added 72 SPD projects in 2025 and 35 more in H1 2026, and deliberately cut low-profit, long-payment-term business.
Retail pharmacy
6.42% of FY2025 revenue (RMB38,382.77 million)A dual-brand chain of Guoda Drugstore stores (7,975 at mid-2026) and hospital-side specialty pharmacies (1,440). Revenue rose 6.67% in FY2025 and 8.58% in H1 2026; Guoda's net loss narrowed from RMB1.104 billion to RMB217 million in 2025.
Other business
Distribution of laboratory supplies, manufacture and distribution of chemical reagents, and production and sale of pharmaceutical products; revenue was RMB8,852.93 million in FY2025 before eliminations (-2.78%).
Strategic priorities
- Network consolidation and M&A
- Optimise the national distribution and logistics network, carry out mergers and acquisitions around the main business and clean up non-core assets, in 2026, the first year of the 15th Five-Year Plan.
- Unified intelligent supply chain platform
- Build one platform covering procurement, warehousing, distribution and sales, unify finance, procurement and logistics systems and test artificial intelligence; digital construction covers 15 core departments and 25 key projects.
- Innovative-drug commercialisation services
- Build a 'second growth curve' in CSO marketing services, specialty pharmacy, SPD and third-party logistics, as innovative drugs are kept out of centralized procurement.
- Retail quality over store count
- Raise single-store quality and own-brand share at Guoda, convert stores into community health stations, and open hospital-side specialty pharmacies.
- Cash flow, lean cost and compliance
- Shift from scale to quality and cash flow: the overall expense ratio fell to 4.11% in H1 2026, 'per capita profit' is a core indicator, and a compliance system lists 53 key prevention and control items.
Latest results
In H1 2026 Sinopharm's revenue was RMB282,799.61 million (-1.13%) and net profit RMB5,179.80 million (-2.95%), with profit attributable to owners of the parent of RMB3,403.77 million (-1.79%). Pharmaceutical distribution revenue fell 1.39% and its operating margin slipped to 2.42%, while retail pharmacy grew 8.58% with a 3.00% margin. The overall expense ratio fell 0.27 point to 4.11% and the gearing ratio was 66.29%. Net cash used in operating activities was RMB23,762.76 million, against RMB34,111.09 million a year earlier. No interim dividend was proposed.
Investments and deals
- Capex in channels, logistics and IT
- Capex was RMB1,917.30 million in FY2025, mainly distribution channels, logistics and IT, and RMB1,578.86 million in H1 2026.
- Hospital SPD and centralised distribution projects
- 72 SPD projects and 68 single-hospital centralised distribution projects added in 2025, and 35 SPD and 28 centralised distribution projects in H1 2026.
- Guoda health stations
- Sinopharm Accord's Guoda built 30 flagship health stations and upgraded 1,000 community stations, with training for 25,000 staff including 4,000 chronic-disease specialists.
- Procurement integration platform
- A procurement integration and centralised procurement platform was launched in H1 2026; AI prescription review and member operations are being deployed in retail.
Challenges and risks
- Volume-based procurement and price cuts
- VBP, price cuts for nationally negotiated drugs and medical insurance cost control pushed distribution revenue down and the gross margin to 7.25% in FY2025 from 7.57%.
- Long hospital payment cycles
- Trade receivables turnover rose to 130 days in FY2025 from 121, and trade and bills receivables reached RMB205,622 million; management expects payment cycles to keep lengthening.
- Compliance pressure
- Tighter state regulation of the industry and of medical insurance funds ranks third among the Board's major risks.
- Device procurement headwinds
- IVD reagent VBP and centralised procurement of large equipment cut device sales; the segment margin was 1.77% in H1 2026.
What leadership says
“industry competition has shifted from scale competition to comprehensive strength competition of efficiency, service, innovation and compliance.”
“the biggest operation highlight of the year”
“scale-oriented to quality and cash flow-oriented”
Where a supplier can help
- Supply chain digitisation
- The unified intelligent supply chain platform and the integration of finance, procurement and logistics systems call for warehouse, traceability and integration software and services.
- Receivables and cash collection tools
- Lengthening hospital payment cycles and the focus on cash flow make receivables management, credit analytics and collection automation relevant.
- Hospital SPD and logistics equipment
- The steady stream of new SPD and centralised distribution projects creates demand for hospital logistics automation, cold-chain and inventory systems.
- Retail health services and AI
- Health stations, AI prescription review and own-brand growth at Guoda open room for retail analytics, testing equipment and staff training providers.
- Compliance management
- The full-coverage compliance system and its 53 key control items suit compliance monitoring and audit software vendors.
Tamtam's reading of the priorities and challenges above, not the company's own words.
Selling to companies like Sinopharm?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companiesKey documents
Read in full by Tamtam; each summary links to the document itself.
- Sinopharm Group Co. Ltd. Annual Report 2025
- Sinopharm Group Co. Ltd. (HKEX 01099), the core listed subsidiary of the state-owned China National Pharmaceutical Group (CNPGC), is a top-rank distributor and retailer of drugs, medical devices and healthcare products running the largest national pharmaceutical and medical device distribution network in China; CNPGC holds 51% of Sinopharm Industrial Investment, which owns 50.36% of the Company, plus 6.64% directly.
- FY2025 revenue was RMB575,167.88 million (-1.60%); profit for the year RMB10,834.43 million (+3.94%); profit attributable to owners of the parent RMB7,155.09 million (+1.50%); basic EPS RMB2.29; proposed final dividend RMB0.69 per share.
- Segments: pharmaceutical distribution RMB435,391.60 million (72.79% of revenue, -2.02%), medical device distribution RMB115,537.72 million (19.32%, -2.02%), retail pharmacy RMB38,382.77 million (6.42%, +6.67%), other business RMB8,852.93 million (-2.78%).
- Retail turnaround: Guoda Drugstore's net loss narrowed from RMB1.104 billion to RMB217 million; it closed a net 1,348 stores to 8,221, while specialty pharmacy sales grew more than 15%.
- Cost and cash discipline: overall expense ratio down 0.25 percentage point to 4.52%; operating cash inflow RMB14,138.21 million (+22.45%); gearing ratio 65.63% (-2.12 points); headcount 94,910 vs 108,217.
- Working-capital strain persists: trade receivables turnover rose to 130 days from 121; trade and bills receivables reached RMB205,622 million.
- 2026 priorities (first year of the 15th Five-Year Plan): network consolidation and M&A around the core business, a unified intelligent supply chain platform, innovative-drug commercialisation services (CSO, specialty pharmacy, SPD), lean cost control and compliance.
- Major risks ranked by the Board: policy risk (volume-based procurement, medical insurance payment reform), cash flow risk (longer hospital payment cycles), compliance risk.
- New leadership: Jin Bin became Chairman on 19 December 2025, replacing Zhao Bingxiang; Lian Wanyong has been President since August 2024.
- Sinopharm Group Co. Ltd. Announcement on 2026 Interim Results
- H1 2026 revenue RMB282,799.61 million (-1.13%); net profit RMB5,179.80 million (-2.95%); profit attributable to owners of the parent RMB3,403.77 million (-1.79%); basic EPS RMB1.09; no interim dividend.
- Pharmaceutical distribution RMB215,496.05 million (72.98% of revenue, -1.39%), operating margin 2.42% (-0.16 point); national negotiated varieties sales +27% and innovative drugs +30% (management statistics).
- Medical device distribution RMB56,854.02 million (19.25%, -0.35%), operating margin 1.77%; 35 new SPD projects and 28 single-hospital centralised distribution projects.
- Retail pharmacy RMB18,635.02 million (6.31%, +8.58%), operating margin 3.00% (+0.32 point); Guoda Drugstore sales -2.4%, 7,975 stores; specialty pharmacy 1,440 stores.
- Overall expense ratio 4.11% (-0.27 point); accounts receivable balance -2.83%; gearing 66.29%.
- Strategic partners' share of drug sales reached 60%; CSO marketing service revenue grew at double digits as the Group builds a "second growth curve" in services.
- Policy tailwinds cited: the 15th Five-Year Plan for National Health, "no centralized procurement for innovative drugs", and population ageing; headcount 90,447.
- Sinopharm Accord FY2025 results briefing — investor relations activity record 2026-01
- Results briefing of Sinopharm Accord (Shenzhen 000028), Sinopharm Group's listed subsidiary for Guangdong/Guangxi distribution and the Guoda Drugstore chain, held 10 April 2026 with General Manager Li Jinxiong and CFO Gu Guolin (Chinese record; quotes translated).
- 2025: revenue RMB73.416 billion (734.16亿元, -1.29%); net profit attributable RMB1.136 billion (11.36亿元, +76.80%); cash dividends above 30% of net profit for two years plus a 1-for-10 bonus share issue.
- Guoda Drugstore turned profitable in 2025; 2026 brings no more large-scale store closures, with the focus on single-store quality.
- Own brands: about RMB2 billion (20亿元) of sales in 2025, up from under 10% to about 15% of regular retail sales.
- Distribution priorities: grassroots network, SPD investment, specialty pharmacies, hospital access for new drugs, narcotics/psychotropics licences (Zhaoqing first), the Hong Kong/Macau drugs and devices channel (over RMB80 million (8000万元) in 2025, doubled).
- Risks: industry-wide lengthening of receivable cycles; medical insurance direct settlement speeds collection only for VBP and negotiated drugs.
- Sinopharm Accord H1 2026 results briefing — investor relations activity record 2026-02
- Results briefing of Sinopharm Accord (Shenzhen 000028), Sinopharm Group's listed subsidiary, held 17 September 2026 with General Manager Li Jinxiong and CFO Gu Guolin (Chinese record; quotes translated).
- H1 2026: revenue RMB36.266 billion (362.66亿元, -1.44%); net profit attributable RMB606 million (6.06亿元, -8.97%); debt ratio 54.55%.
- Distribution revenue 265.39亿元 (-0.91%), net profit 4.60亿元; national negotiated drug sales +23%; innovative drugs +25% to about 18% of distribution sales.
- Guoda Drugstore revenue 102.27亿元 (-2.40%), net profit 0.13亿元; 7,975 stores; centralised purchasing above 70%, own brands about 15%.
- Health services push: 30 flagship and 1,000 community "health stations"; training for 25,000 staff including 4,000 chronic-disease specialists.
- About 160 specialty pharmacies in Guangdong and Guangxi (119 dual-channel), sales up about 20%; nuclear medicine licence prepared in Guangzhou.
- Dividend: no interim payout; cash payout kept at no less than 30% of net profit.
Questions about Sinopharm
What does Sinopharm Group do?
Sinopharm Group distributes drugs, medical devices and healthcare products across China through the largest national distribution network, runs the Guoda Drugstore and specialty pharmacy chains, and makes pharmaceutical products and lab supplies.
What is Sinopharm Group's revenue?
FY2025 revenue was RMB575,167.88 million (-1.60%), with profit attributable to owners of the parent of RMB7,155.09 million. H1 2026 revenue was RMB282,799.61 million (-1.13%).
How many employees does Sinopharm Group have?
90,447 at mid-2026, down from 94,910 at end-2025 and 108,217 a year earlier.
Who leads Sinopharm Group?
Jin Bin became Chairman on 19 December 2025, replacing Zhao Bingxiang; Lian Wanyong has been President since August 2024.
Who owns Sinopharm Group?
The state-owned CNPGC holds 51% of Sinopharm Industrial Investment, which owns 50.36% of the Company, plus 6.64% directly; Shanghai Fosun Pharmaceutical holds the other 49% of Sinopharm Industrial Investment.
Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)